Skip to main content
SpringerLink
Log in

CT-P10 (Truxima™): A Rituximab Biosimilar

  • Adis Biosimilar Brief
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

CT-P10 (Truxima™) is the first biosimilar of the reference monoclonal anti-CD20 antibody rituximab. It is approved for use in all indications for which reference rituximab is approved, including follicular lymphoma (FL), diffuse large B-cell non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis (RA), granulomatosis with polyangiitis and microscopic polyangiitis. CT-P10 has similar physicochemical and pharmacodynamic properties to those of reference rituximab, and the pharmacokinetic biosimilarity of the agents has been shown in patients with RA or FL. CT-P10 demonstrated clinical efficacy equivalent to that of reference rituximab in patients with RA, and was generally well tolerated in this population as well as in patients with FL. The tolerability, immunogenicity and safety profiles of CT-P10 were similar to those of reference rituximab, and switching from reference rituximab to CT-P10 had no impact on safety or efficacy. The role of reference rituximab in the management of autoimmune conditions and cancers is well established and CT-P10 provides an effective biosimilar alternative for patients requiring rituximab therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Celltrion Healthcare. Truxima 500 mg concentrate for solution for infusion: EU summary of product characteristics. 2017. http://ec.europa.eu/health/documents/community-register/html/h1167.htm. Accessed 4 Apr 2017.

  2. European Medicines Agency. Assessment report: Truxima (international non-proprietary name: rituximab). 2016. http://www.ema.europa.eu. Accessed 4 Apr 2017.

  3. Yoo DH, Suh C-H, Shim SC, et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(3):566–70.

    Article  PubMed  Google Scholar 

  4. Yoo DH, Bozic Majstorovic L, Berrocal KA, et al. Efficacy and safety of CT-P10, rituximab biosimilar candidate, and innovator rituximab in patients with rheumatoid arthritis: results from phase 3 randomized controlled trial over 24 weeks [abstract no. 1635]. Arthritis Rheumatol. 2016;68(Suppl 10):2040–2.

    Google Scholar 

  5. Yoo DH, Park W, Suh C-H, et al. Efficacy and safety of rituximab biosimilar candidate (CT-P10) and innovator rituximab in patients with rheumatoid arthritis: results from phase I randomized controlled trial over 72 weeks [abstract no. 2058]. Arthritis. Rheumatol. 2015;67(Suppl 10):2449–52.

    Google Scholar 

  6. Coiffier B, Sancho J-M, Jurczak W, et al. Pharmacokinetic and safety of CT-P10, a biosimilar candidate to the rituximab reference product, in patients with newly diagnosed advanced stage follicular lymphoma (AFL) [abstract]. Blood. 2016;128(22):1807.

    Google Scholar 

  7. US National Institutes of Health. ClinicalTrials.gov identifier NCT02149121. 2017. http://www.clinicaltrials.gov. Accessed 4 Apr 2017.

  8. Yoo DH, Park W, Suh C-H, et al. Efficacy and safety of switched CT-P10 from innovator rituximab compared to those of maintained CT-P10 in patients with rheumatoid arthritis up to 56 weeks [abstract no. 1675]. Arthritis. Rheumatol. 2015;67(Suppl 10):2067–9.

    Google Scholar 

  9. Park W, Yoo DH, Suh CH, et al. Comparable time to retreatment with CT-P10 and innovator rituximab up to 2 years in patients with active rheumatoid arthritis [abstract no. THU0162]. Ann Rheum Dis. 2016;75(Suppl 2):241–2.

    Article  Google Scholar 

  10. Suh CH, Berrocal KA, Chalouhi E-KE, et al. Pharmacokinetics and safety of three formulations of rituximab (CT-P10, US-sourced innovator rituximab and EU-sourced innovator rituximab) in patients with rheumatoid arthritis: results from phase 3 randomized controlled trial over 24 weeks [abstract no. 1634]. Arthritis. Rheumatol. 2016;68(Suppl 10):2038–40.

    Google Scholar 

  11. Gulacsi L, Brodszky V, Baji P, et al. The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries. Adv Ther. 2017. doi:10.1007/s12325-017-0522-y.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Emma D. Deeks

Authors
  1. Emma D. Deeks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emma D. Deeks.

Ethics declarations

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Emma Deeks is a salaried employee of Adis/Springer.

Additional information

The manuscript was reviewed by: F. Araújo, Rheumatology and Osteoporosis Unit, Hospital Ortopédico de Sant’Ana, SCML, Parede, Portugal; W. Park, Medicine/Rheumatology, Inha University Medical School, Incheon, Republic of Korea; W. R. Strohl, BiStro Biotech Consulting, Bridgewater, NJ, USA.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deeks, E.D. CT-P10 (Truxima™): A Rituximab Biosimilar. BioDrugs 31, 275–278 (2017). https://doi.org/10.1007/s40259-017-0226-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40259-017-0226-5

Keywords

Search

Navigation